Active	Status	Sponsor type	Region	Phase	Filter
7 Active 8 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Xu, Xun
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD	Recruiting	3	388	RoW	HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis	Shanghai Henlius Biotech	Age Related Macular Degeneration	08/23	03/24
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD	Completed	3	410	Europe, US, RoW	HLX04-O, ranibizumab	Shanghai Henlius Biotech	Age Related Macular Degeneration	12/24	12/24
NCT04187443: MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema	Suspended	1	45	RoW	MS-553	Shenzhen MingSight Relin Pharmaceuticals Co., Ltd., Fountain Medical Development Co., Ltd.	Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema, Diabetic Retinopathy	06/25	07/25
SESOP, NCT03455478: Shanghai Eye Study for Adults	Recruiting	N/A	1000000	RoW	spectacles	Shanghai Eye Disease Prevention and Treatment Center, Brien Holden Vision	Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging	11/19	11/26
Zhuang, Wenjuan
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD	Completed	3	410	Europe, US, RoW	HLX04-O, ranibizumab	Shanghai Henlius Biotech	Age Related Macular Degeneration	12/24	12/24